Finally, we explored the therapeutic effect of anti-TGF-β and anti-PD-1 combination therapy in malignant pleural effusions from EGFR-mutated NSCLC patients after EGFR-TKI failure. This evidence concerns the gene TGFB1 and non-small cell lung carcinoma.